Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.
Swain, N.A., Batchelor, D., Beaudoin, S., Bechle, B.M., Bradley, P.A., Brown, A.D., Brown, B., Butcher, K.J., Butt, R.P., Chapman, M.L., Denton, S., Ellis, D., Galan, S.R.G., Gaulier, S.M., Greener, B.S., de Groot, M.J., Glossop, M.S., Gurrell, I.K., Hannam, J., Johnson, M.S., Lin, Z., Markworth, C.J., Marron, B.E., Millan, D.S., Nakagawa, S., Pike, A., Printzenhoff, D., Rawson, D.J., Ransley, S.J., Reister, S.M., Sasaki, K., Storer, R.I., Stupple, P.A., West, C.W.
J. Med. Chem.